文献速递淋巴瘤造血干细胞移植与细胞治疗

自体造血干细胞移植后来那度胺维持治疗套细胞淋巴瘤:FIL多中心随机3期试验结果

Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2020-12-22

这项开放标签、随机、多中心3期试验在意大利和葡萄牙49个中心纳入300例初治套细胞淋巴瘤患者,诱导治疗后行自体HSCT,缓解者随机接受24个月来那度胺维持或观察。

要点

  • 自体HSCT后来那度胺维持可改善套细胞淋巴瘤的PFS(3年PFS 80% vs 64%)。
  • 来那度胺组3-4级血液学不良事件发生率63%,显著高于观察组12%。
  • 来那度胺组3-4级非血液学不良事件31%,感染最常见,需密切监测。

核心结论

  • 尽管毒性不可忽视,自体HSCT后来那度胺维持改善了套细胞淋巴瘤患者的无进展生存期。

研究设计与样本

  • 开放标签、随机、多中心3期试验,在意大利和葡萄牙49个血液肿瘤中心开展。
  • 300例初治套细胞淋巴瘤患者入组,中位年龄57岁(IQR 51-62),235例(78%)为男性。
  • 诱导方案包括R-CHOP、大剂量环磷酰胺和R-HD-阿糖胞苷,缓解后行自体HSCT。
  • 移植后缓解且血液学恢复的患者按1:1随机接受24个周期来那度胺维持(104例)或观察(101例)。
  • 主要终点为随机人群的无进展生存期。

主要发现

  • 中位随访38个月(IQR 24-50),3年PFS来那度胺组80%(95%CI 70-87),观察组64%(95%CI 53-73)。
  • 来那度胺组41例(39%)因死亡或疾病进展等原因停药。
  • 来那度胺组治疗相关死亡2例(2%),观察组1例(1%)。

关键数值与推荐

  • 来那度胺剂量:血小板>100×10^9/L者15 mg/日,血小板60-100×10^9/L者10 mg/日,第1-21天给药,每28天一次。
  • 严重不良事件来那度胺组22例(24%),观察组5例(5%)。

临床怎么用

  • 对于自体HSCT后缓解的套细胞淋巴瘤患者,可考虑来那度胺维持以延长PFS。
  • 维持期间需密切监测血液学毒性和感染,及时调整剂量和处理不良事件。

局限性

  • 开放标签设计可能影响不良事件报告和临床决策。
  • 随机前排除95例患者,可能影响结果的外推性。
  • 随访时间较短(中位38个月),总生存数据尚未成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fit patients with mantle cell lymphoma aged 18-65 years are usually given cytarabine and rituximab-based induction regimens followed by autologous haematopoetic stem-cell transplantation (HSCT). We investigated whether post-autologous HSCT maintenance with lenalidomide improves progression-free survival in this population. METHODS: This open-label, randomised, multicentre, phase 3 trial was done at 49 haematology and oncology units in Italy and Portugal. Eligible patients had Ann Arbor stage III or IV treatment-naive mantle cell lymphoma (or stage II plus bulky disease [≥5 cm] or B symptoms), and had evidence of cyclin D1 overexpression or the translocation t(11;14)(q13;q32). Patients were aged 18-59 years with Eastern Cooperative Oncology Group (ECOG) performance status 0-3, or aged 60-65 years with ECOG 0-2. After an optional prephase with vincristine and steroids (intravenous vincristine 1·4 mg/m2 on day 1, oral prednisone 100 mg [total dose] on days 1-5), patients were given three courses of R-CHOP (21-day cycle, intravenous rituximab 375 mg/m2 on day 1; intravenous doxorubicin 50 mg/m2, vincristine 1·4 mg/m2, and cyclophosphamide 750 mg/m2 on day 2; oral prednisone 100 mg/m2 on day 2-6). Patients then received one cycle of high-dose CTX (intravenous cyclophosphamide 4 g/m2 on day 1, intravenous rituximab 375 mg/m2 on day 4). After restaging, patients received two cycles of R-HD-cytarabine (high-dose intravenous cytarabine 2 g/m2 every 12 h on days 1-3, intravenous rituximab 375 mg/m2 on days 4 and 10). Patients with complete remission or partial remission proceeded to autologous HSCT and responding patients (complete remission or partial remission) with haematological recovery were randomly assigned (1:1) to receive 24 courses of oral lenalidomide maintenance (15 mg per day for patients with platelets >100 × 109 cells per L or 10 mg per day for platelets 60-100 × 109 cells per L, days 1-21 every 28 days) for 24 months, or observation. The primary endpoint was progression-free survival, measured in the randomised population. This study is registered with EudraCT (2009-012807-25) and ClinicalTrials.gov (NCT02354313). FINDINGS: Between May 4, 2010, and Aug 24, 2015, 303 patients were screened for inclusion and 300 patients were enrolled (median age 57 years, IQR 51-62; 235 [78%] male). 95 patients were excluded before randomisation, mostly due to disease progression, adverse events, and inadequate recovery. 104 patients were randomly assigned to the lenalidomide maintenance group and 101 patients to the observation group. 11 (11%) of 104 patients assigned to lenalidomide did not start treatment (3 withdrew, 6 adverse events or protocol breach, 2 lost to follow-up). At a median follow-up of 38 months after randomisation (IQR 24-50), 3-year progression-free survival was 80% (95% CI 70-87) in the lenalidomide group versus 64% (53-73) in the observation group (log-rank test p=0·012; hazard ratio 0·51, 95% CI 0·30-0·87). 41 (39%) of 104 patients discontinued lenalidomide for reasons including death or progression. Treatment-related deaths were recorded in two (2%) of 93 patients in the lenalidomide group (1 pneumonia, 1 thrombotic thrombocytopenic purpura), and one (1%) of 101 in the observation group (pneumonia). 59 (63%) of 93 patients in the lenalidomide group had grade 3-4 haematological adverse events versus 12 (12%) of 101 patients in the observation group (p<0·0001). 29 (31%) of 93 patients in the lenalidomide group and eight (8%) of 101 patients in the observation group had grade 3-4 non-haematological adverse events (p<0·0001), of which infections were the most common.Serious adverse events were reported in 22 (24%) of 93 patients in the lenalidomide group and five (5%) of 101 patients in the observation group. Pneumonia and other infections were the most common serious adverse events. INTERPRETATION: Despite non-negligibile toxicity, lenalidomide after autologous HSCT improved progression-free survival in patients with mantle cell lymphoma, highlighting the role of maintenance in mantle cell lymphoma. FUNDING: Fondazione Italiana Linfomi and Celgene.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Ladetto M, Cortelazzo S, Ferrero S, et al. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. Lancet Haematol. 2020. PMID: 33357480. doi:10.1016/S2352-3026(20)30358-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。